Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMWOF1E)

Drug Name
SKY59 Drug Info
Synonyms Crovalimab; RO7112689
Indication
Disease Entry ICD 11 Status REF
Haemolytic uraemic syndrome 3A21.2 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMWOF1E

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C5 (CO5) TTKANGO CO5_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Haemolytic uraemic syndrome
ICD Disease Classification 3A21.2
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement C5 (CO5) DTT C5 7.69E-01 -0.12 -0.23
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04861259) A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-a). U.S. National Institutes of Health.
2 The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912-920.